4 rue Pierre Fontaine
91058 EVRY Cedex – France
Email : email@example.com
Zakia BELAID-SANDAL : CEO
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.Discover >
Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases
Young and multidisciplinary French start-up, THERANOVIR develops immunotherapeutic innovative antibodies for three diversified and interconnected pathologies:
This project is the result of academic research
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
The main axe of THERANOVIR is oncology. THERANOVIR is developing innovative therapeutic monoclonal antibodies targeting both tumor cells (stem and non-stem) and cells of the microenvironment in combination with a companion immunohistological test. Being in the preclinical phases, candidates under development will be proposed in combination in response to therapeutic failures of checkpoint inhibitors and / or anti-angiogenesis in combination with chemotherapy.
At the same time, THERANOVIR is progressing in the development of immunotherapeutic antibodies targeting obesity.
THERANOVIR is currently looking for funding to progress in the preclinical development in order to enter the regulatory and the clinical phases.
We are interested to tie partnerships with big pharma to ensure the development of our products in clinical phases and beyond.
The IP is protected by a family of 2 patents covering Europe, US and Asia that THERANOVIR exploits via a global and exclusive license from INSERM Transfert.
Cohesive and complementary skilled team, 100% of employees are PhD holders. THERANOVIR is supported by an advisory board represented by KOL experts.
THERANOVIR is surrounded by an ecosystem supporting innovations and specially startup in Health-Tech represented by Genopole, Medicen, Mabdesign, France Biotech, Bpifrance, Region Ile-de-France.
The target is a new complex of proteins expressed in many cancer types which allows us to propose an agnostic therapy.
The offer is complete including companion test to identify if the treatment is effective on the patient and the therapy itself.
The therapy is validated in vitro and in vivo recently and until today, there is no treatment targeting this protein complex in the pharmacopeia.
In same field
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.Discover
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).Discover
Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.Discover
GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.Discover
By means of its autonomous messenger RNA synthesis platform, Eukarÿs develops 1) systems for the bioproduction of viruses and recombinant proteins and 2) preventative vaccines for viral infectious diseases and treatments in immuno-oncology.Discover
Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.Discover
Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.Discover